In collaboration with Microsoft and NVIDIA,
SOPHiA GENETICS is developing a comprehensive whole genome
analytical solution
BOSTON and ROLLE,
Switzerland, May 29, 2024 /PRNewswire/ -- SOPHiA GENETICS
(Nasdaq: SOPH), a cloud-native healthcare technology company and a
global leader in data-driven medicine, today announced that it
is collaborating with Microsoft and NVIDIA to leverage their
expertise in technology and genomics to bring a streamlined and
scalable whole genome sequencing (WGS) analytical solution to
healthcare institutions, with the aim to make the solution
available to customers before the end of the year.
The new WGS application from SOPHiA GENETICS will be designed to
provide fully analyzed whole genome insights in an accelerated
timeline, enabling researchers and clinicians to make data-driven
decisions within the same day. This expedited speed will also
increase opportunities for researchers and biotechnology companies
to innovate rapidly across clinical research, drug discovery and
care delivery with improved efficiency and effectiveness.
"By leveraging the powerful technologies and capabilities
offered by Microsoft Azure and NVIDIA, we are working to provide
accurate, scalable, and rapid insights across multiple modalities,
helping benefit our customers and, ultimately, patients,
particularly those living with rare inherited disorders," said
Abhimanyu Verma, Chief Technology
Officer, SOPHiA GENETICS. "We are
confident our new WGS application will help provide an answer to
existing customer needs and expedite research, diagnosis and
treatment planning worldwide."
The SOPHiA DDM™ Platform is a tech-agnostic, universal
cloud-based Software-as-a-Service platform that enables healthcare
institutions to get quick, robust, and actionable insights from
their data. SOPHiA GENETICS' technology analyzes genomic data,
alongside other modalities – including diagnostic details, imaging,
pathology, and medical assessments – to provide clear insights for
institutions worldwide. The collective intelligence garnered from
SOPHiA DDM™ supports discoveries, treatment decisions, and drug
development efforts, benefiting patients with cancer and rare
inherited genetic disorders.
As part of this collaboration, SOPHiA DDM™, hosted on Azure,
will be powered by NVIDIA Parabricks for SOPHiA DDM™'s WGS
application. NVIDIA Parabricks is a scalable genomics analysis
software suite that leverages full-stack NVIDIA accelerated
computing to process whole genomes in minutes. Compatible with all
leading sequencing instruments, Parabricks supports diverse
bioinformatics workflows and integrates artificial intelligence
(AI) for accuracy and customization. SOPHiA GENETICS will also
use powerful NVIDIA GPUs on Azure to process computationally heavy
workloads, providing a scalable and efficient solution.
"Whole-genome sequencing has the potential to enhance and
accelerate treatment plans and drug development efforts," said
George Vacek, Global Head of
Genomics Alliances, NVIDIA. "Powered by NVIDIA Parabricks, SOPHiA
DDM can process whole genomes in minutes, unlocking new
possibilities and and helping drive meaningful impact for patients
worldwide."
"Microsoft aims to propel healthcare and life sciences into an
exciting new era of personalized medicine, helping unlock
transformative possibilities for patients worldwide," said
Peter Durlach, corporate vice
president, Health & Life Sciences, Microsoft. "Our longstanding
work with SOPHiA GENETICS and this latest collaboration leveraging
Microsoft Azure and NVIDIA technology to create a new whole genome
sequencing application, will have the potential to accelerate vital
health research worldwide."
For more information on SOPHiA GENETICS,
visit SOPHiAGENETICS.COM, connect on LinkedIn, or
visit the SOPHiA GENETICS booth at ESHG 2024.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare
technology company on a mission to expand access to
data-driven medicine by using AI to deliver world-class care to
patients with cancer and rare disorders across the globe.
It is the creator of the SOPHiA DDM™ Platform, which analyzes
complex genomic and multimodal data and generates real-time,
actionable insights for a broad global network of hospital,
laboratory, and biopharma institutions. For more information,
visit SOPHiAGENETICS.COM and connect with us
on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking
Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products, and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this press release
speak only as of the date hereof. We expressly disclaim any
obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-to-launch-new-whole-genome-sequencing-capabilities-302157975.html